4D Molecular Therapeutics (4DMT) Stock

4dmoleculartherapeutics.comHealthcare / BioTech & PharmaFounded: 2013

4DMT is a biotechnology company focused on pioneering the development of precision gene therapies based on proprietary AAV vectors.

Register To Buy and Sell Private Company Shares

For more details on financing and valuation of private companies similar to 4D Molecular Therapeutics (4DMT) before its IPO, register or login today.

Please provide a valid email address.

By registering, you agree to Forge’s Terms of Use. Already registered? Log in

4D Molecular Therapeutics (4DMT) Stock Price

Forge Price 1
Price not available
Last Closed Trade 2
Close Date
xx/xx/xx
Last Closed Trade Price
$xx.xx
Last Funding Round (LFR)
Date
xx/xx/xx
Price per Share
$xx.xx

4D Molecular Therapeutics (4DMT) Funding Rounds and Valuation

Funding History Chart
Funding Round Details
Funding Date Share Class Amount Raised Price per Share Post-Money Valuation Key Investors
Funding Round Details are not yet available for this company.

Leadership & Board

Leadership

David Kirn MD
Chief Executive Officer, Chairman & Co-Founder
Melissa Kotterman Ph.D
Vice President, Discovery & Engineering & Co-Founder
August Moretti JD
Chief Financial Officer
Fred Kamal Ph.D
Chief Technology Officer
Peter Francis MD
Chief Medical Officer
Theresa Janke
Co-Founder & Chief Operating Officer
Leisa Johnson
Vice President, Pre-Clinical R&D, Pharmacology & Toxicology Program Leader, Lung Therapeutic Area
David Schaffer Ph.D
Co-Founder, Chief Scientific Advisor & Board Member

Board

Charles Theuer MD
Self
Deborah Marshall JD
Sidley Austin
Margi McLaughlin Ph.D
Self
David Schaeffer Ph.D
Hoyoung Huh Ph.D
Self
David Kirn MD
4DMT
Jacob Chacko MD
Self
Tony Yao Ph.D
ArrowMark Partners

4D Molecular Therapeutics (4DMT) stock FAQs

plusminus

Can you buy 4D Molecular Therapeutics (4DMT) stock?

You can no longer buy 4D Molecular Therapeutics (4DMT) stock on a secondary marketplace as this company is no longer private. If you are interested in buying stock of other private companies, learn more about how to invest in the private market or register today to get started.
plusminus

How to buy 4D Molecular Therapeutics (4DMT) stock?

You can no longer buy 4D Molecular Therapeutics (4DMT) stock on a secondary marketplace as this company is no longer private. If you are interested in buying stock of other private companies, learn more about how to invest in the private market or register today to get started.
plusminus

Can you sell 4D Molecular Therapeutics (4DMT) stock?

You can no longer sell stock of 4D Molecular Therapeutics (4DMT) on Forge as this company is no longer private. However, if you own stock of a private company, Forge may help you sell it in a way that works for you and the company. Learn more or register with us today to get started.
plusminus

How to sell 4D Molecular Therapeutics (4DMT) stock?

You can no longer sell stock of 4D Molecular Therapeutics (4DMT) on Forge as this company is no longer private. However, if you own stock of a private company, Forge may help you sell it in a way that works for you and the company. Learn more or register with us today to get started.
plusminus

Is 4D Molecular Therapeutics (4DMT) a public company?

4D Molecular Therapeutics (4DMT) is now a public company traded on NASDAQ with ticker FDMT.
plusminus

What is 4D Molecular Therapeutics (4DMT)’s stock price?

The stock price of 4D Molecular Therapeutics (4DMT) is $17.05 as of 1/18/24.
plusminus

What is 4D Molecular Therapeutics (4DMT)’s stock ticker symbol?

The ticker symbol of 4D Molecular Therapeutics (4DMT) is FDMT.
plusminus

Can institutional investors buy and sell private market stocks?

Yes. As one of the largest trading platform for the private market, Forge helps institutional investors seek liquidity as they buy and sell private stock for their portfolios or their clients. Our private market specialists have decades of experience working with institutional firms. Learn more or register today to get started.

4D Molecular Therapeutics (4DMT) News and Media Highlights

Astellas signs $962m rare eye disease deal with 4D Molecular Therapeutics

Astellas Pharma has signed a $962m deal with 4D Molecular Therapeutics (4DMT) for rights to use one of 4DMT's gene therapy vectors for treating a rare eye disease. The US genetic medicines company will receive $20m upfront for its R100 vector technology and could receive up to $942.5m in future fees and milestones. Astellas will be responsible for research, development, manufacturing, and commercialisation and has an option to add two more disease targets.

4DMT Gains Alignment with FDA on Plan to Lift Clinical Hold on Phase 1/2 INGLAXA Clinical Trial for 4D-310 for Fabry Disease Cardiomyopathy

4D Molecular Therapeutics (4DMT) has achieved alignment with the FDA over a plan to lift a clinical hold on the Phase 1/2 INGLAXA clinical trial involving 4D-310, a treatment for Fabry disease cardiomyopathy. The company has amended the INGLAXA protocol to decrease the risk of atypical hemolytic uremic syndrome (aHUS), and interim clinical data from the trial is expected to be presented in Q1 2024.

Astellas, 4D Molecular Therapeutics Agree to Licensing Deal

Astellas Pharma and 4D Molecular Therapeutics (4DMT) have agreed to a licensing deal that allows Astellas to use 4DMT's intravitreal retinotropic R100 vector. The R100 vector is used for the delivery of genetic payloads in the treatment of retinal diseases. Astellas initially has rights to one genetic target, with the option to include two more for additional fees.

Astellas paves backloaded biobucks deal to test 4DMT's eye disease gene therapy vector

Astellas Pharma has signed a contract to use 4D Molecular Therapeutics’ gene therapy vector for at least one rare eye disease. As part of the deal, 4DMT will receive $20 million upfront, with potential total milestones of $942.5 million. Astellas will use the vector to deliver its own genetic payloads and will be responsible for R&D, manufacturing, and commercialization for the resulting programs. The deal aligns with Astellas' focus on blindness and regeneration as part of its R&D strategy.
Browse Insights
Updated on: Dec 22, 2024

PLEASE READ THESE IMPORTANT LEGAL NOTICES & DISCLOSURES

1. Forge Price™ is a custom data-point calculated and disseminated by Forge Data LLC (“Forge Data”) and is a mark of Forge Data. Forge Price may rely on a very limited number of inputs in its calculation. Forge Price is prepared and disseminated solely for informational purposes. Redistribution is permitted solely with Forge’s written consent. While Forge has obtained information from sources it believes to be reliable, Forge does not perform an audit or undertake any duty of due diligence or independent verification of any information it receives. Forge does not guarantee the accuracy, completeness, timeliness, or availability of Forge Price, and are not responsible for any errors or omissions, regardless of the cause, or any results obtained from the use of Forge Price. Forge Price is derived from secondary activity on the Forge platform and other private market trading platforms, and other publicly-available datapoints collected by Forge.  Forge Price is not intended to, and does not necessarily, represent the market price of any securities (I.e., the price at which you could buy or sell such securities). Neither reference to company names, nor calculation of Forge Price for a specific company, implies any affiliation between Forge and that company, any endorsement or sponsorship by Forge of any company or vice versa, or any partnership, joint venture or other commercial relationship between Forge and any company. Rights with respect to any company marks referred to herein are owned by the company.

2. The Last Closed Trade price displayed reflects the price at which the last trade in this company's security occurred on Forge, and can include secondary trades in any class of the company's security, or trades in units of funds holding the company's securities (the economics of which differ versus direct company ownership). The date displayed reflects the date on which the last trade in this company's security closed on Forge. This may be several weeks after the terms of the trade were agreed upon between the buyer and seller. In case of multiple trades closed on the same date, the price displayed is of either (i) the trade which terms were agreed upon most recently; or (ii) the trade with the higher notional value.

‘Stock Price’ or other private company metrics (‘PC Data’) may rely on a very limited number of trade and/or IOI inputs in their calculation. PC Data is prepared and disseminated solely for informational purposes. While Forge has obtained information from sources it believes to be reliable, Forge does not perform an audit or undertake any duty of due diligence or independent verification of any information it receives. Forge does not guarantee the accuracy, completeness, timeliness, or availability of PC Data, and are not responsible for any errors or omissions, regardless of the cause, or any results obtained from the use of PC Data. PC Data is derived from the performance and pricing of secondary activity on the Forge platform and other private market trading platforms. PC Data is not intended to, and does not necessarily, represent the market price of any securities (I.e., the price at which you could buy or sell such securities). Reference to company names does not imply any affiliation between Forge and that company, any endorsement or sponsorship by Forge of any company or vice versa, or any partnership, joint venture or other commercial relationship between Forge and any company. Rights with respect to any company marks referred to herein are owned by the company.

Public news articles listed on this page have been curated by Forge based on several factors including, but not limited to, product updates, changes in organization structure, funding rounds, third-party valuations, and key personnel changes. Changes to this list of articles can be made at any time without notice and should not be relied upon for investment purposes. Forge does not verify the accuracy of the information contained in public news articles.

Investing in private company securities is not suitable for all investors, is highly speculative, is high risk, and investors should be prepared to withstand a total loss of their investment. Private company securities are highly illiquid and there is no guarantee that a market will develop for such securities. Each investment carries its own risks, and investors should conduct their own due diligence regarding the investment, including obtaining independent professional advice. Past performance is not indicative of future results. This is not a recommendation, offer, solicitation of an offer, or advice to buy or sell securities by Forge, nor an offer of brokerage services in any jurisdiction where Forge is not permitted to offer brokerage services. Brokerage products and services are offered by Forge Securities LLC, a registered broker-dealer and member FINRA/SIPC. Please see other important disclaimers, disclosures and restrictions you acknowledge by using this website and to which you are subject.